Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 23,818 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 23,818 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $46.19, for a total transaction of $1,100,153.42. Following the transaction, the chief executive officer directly owned 143,945 shares in the company, valued at approximately $6,648,819.55. This represents a 14.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00.
• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50.

Tempus AI Price Performance

TEM stock opened at $46.70 on Thursday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company’s 50-day moving average is $51.40 and its 200-day moving average is $52.12. The stock has a market capitalization of $8.39 billion, a PE ratio of -32.43 and a beta of 3.58. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period in the previous year, the company posted ($0.22) EPS. The firm’s revenue was up 21.6% compared to the same quarter last year. Equities research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares during the last quarter. ARK Investment Management LLC grew its position in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC purchased a new stake in Tempus AI in the 4th quarter valued at about $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its position in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TEM shares. Piper Sandler lowered their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research report on Tuesday. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. TD Cowen restated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $64.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.